Chemotherapy dose density in elderly lung cancer patients requires frequent modifications: A retrospective case series from January 2011 to July 2012
Sasithara Ahilathirunayagam(Guy's and St Thomas' NHS Foundation Trust), Rohit Lal, Tania Kalsi(Guy's and St Thomas' NHS Foundation Trust), Friedrich Wittenbecher(Charité - Universitätsmedizin Berlin), M. Ali Zohree(Guy's and St Thomas' NHS Foundation Trust), James Spicer(King's College London), C.E. Moss(Guy's and St Thomas' NHS Foundation Trust), A. Babic-illman(Guy's and St Thomas' NHS Foundation Trust), Danielle Harari(St Thomas' Hospital), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Yasmin Husain(Arabian Gulf University)
Cited by 0
Related Papers
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
|The Lancet Oncology|2019|228
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
|Gynecologic Oncology|2019|104
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
|British Journal of Cancer|2022|89